Akt inhibitors: mechanism of action and implications for anticancer therapeutics

被引：34

作者：

Bhutani, Jaikrit ^{[1
]}

Sheikh, Asfandyar ^{[2
,4
]}

Niazi, Asfandyar Khan ^{[3
]}

机构：

[1] Post Grad Inst Med Sci, Rohtak, Haryana, India

[2] Dow Univ Hlth Sci, Dow Med Coll, Karachi, Pakistan

[3] Shifa Coll Med, Islamabad, Pakistan

[4] Pakistan Res Evolut Sci Soc, Karachi 74200, Pakistan

来源：

INFECTIOUS AGENTS AND CANCER | 2013年 / 8卷

关键词：

SIGNAL-TRANSDUCTION; PROSTATE-CANCER; CELL-SURVIVAL; KINASE; GROWTH; CARCINOMAS; EXPRESSION; ONCOGENE; PATHWAY; GLIOBLASTOMAS;

D O I：

10.1186/1750-9378-8-49

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Akt, better known as protein kinase B (PKB), is a serine/threonine-specific protein kinase which acts as mediator via PI3K/Akt pathway in many biological processes like glucose metabolism, apoptosis, cell differentiation and transcription. Akt1 gene amplification has been implicated in gastric carcinoma while Akt2 amplification has been linked with ovarian, pancreas, breast and stomach tumors. The use of Akt inhibitors as monotherapy or in combination with other anticancer drugs could be useful for combating drug resistance and improving response. Thus, comprehensive understanding of Akt and its linked signaling pathways (PI3K, PKB, mTOR etc.) is necessary to lead to newer drug development and use.

引用

页数：4

共 36 条

[1] Cell survival and metastasis regulation by Akt signaling in colorectal cancer [J].

Agarwal, Ekta ;

Brattain, Michael G. ;

Chowdhury, Sanjib .

CELLULAR SIGNALLING, 2013, 25 (08) :1711-1719

[2] The Akt/PKB family of protein kinases: A review of small molecule inhibitors and progress towards target validation [J].

Barnett, SF ;

Bilodeau, MT ;

Lindsley, CW .

CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2005, 5 (02) :109-125

[3] MOLECULAR ALTERATIONS OF THE AKT2 ONCOGENE IN OVARIAN AND BREAST CARCINOMAS [J].

BELLACOSA, A ;

DEFEO, D ;

GODWIN, AK ;

BELL, DW ;

CHENG, JQ ;

ALTOMARE, DA ;

WAN, MH ;

DUBEAU, L ;

SCAMBIA, G ;

MASCIULLO, V ;

FERRANDINA, G ;

PANICI, PB ;

MANCUSO, S ;

NERI, G ;

TESTA, JR .

INTERNATIONAL JOURNAL OF CANCER, 1995, 64 (04) :280-285

[4] Discovery and Preclinical Pharmacology of a Selective ATP-Competitive Akt Inhibitor (GDC-0068) for the Treatment of Human Tumors [J].

Blake, James F. ;

Xu, Rui ;

Bencsik, Josef R. ;

Xiao, Dengming ;

Kallan, Nicholas C. ;

Schlachter, Stephen ;

Mitchell, Ian S. ;

Spencer, Keith L. ;

Banka, Anna L. ;

Wallace, Eli M. ;

Gloor, Susan L. ;

Martinson, Matthew ;

Woessner, Richard D. ;

Vigers, Guy P. A. ;

Brandhuber, Barbara J. ;

Liang, Jun ;

Safina, Brian S. ;

Li, Jun ;

Zhang, Birong ;

Chabot, Christine ;

Do, Steven ;

Lee, Leslie ;

Oeh, Jason ;

Sampath, Deepak ;

Lee, Brian B. ;

Lin, Kui ;

Liederer, Bianca M. ;

Skelton, Nicholas J. .

JOURNAL OF MEDICINAL CHEMISTRY, 2012, 55 (18) :8110-8127

[5] AKT2, A PUTATIVE ONCOGENE ENCODING A MEMBER OF A SUBFAMILY OF PROTEIN-SERINE THREONINE KINASES, IS AMPLIFIED IN HUMAN OVARIAN CARCINOMAS [J].

CHENG, JQ ;

GODWIN, AK ;

BELLACOSA, A ;

TAGUCHI, T ;

FRANKE, TF ;

HAMILTON, TC ;

TSICHLIS, PN ;

TESTA, JR .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1992, 89 (19) :9267-9271

[6] Amplification of AKT2 in human pancreatic cancer cells and inhibition of ATK2 expression and tumorigenicity by antisense RNA [J].

Cheng, JQ ;

Ruggeri, B ;

Klein, WM ;

Sonoda, G ;

Altomare, DA ;

Watson, DK ;

Testa, JR .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (08) :3636-3641

[7]

ClinicalTrials.gov, STUD INV AKT INH GSK

[8]

ClinicalTrials.gov, OP LAB PHAS 2 STUD O

[9] Severe diabetes, age-dependent loss of adipose tissue, and mild growth deficiency in mice lacking Akt2/PKBβ [J].

Garofalo, RS ;

Orena, SJ ;

Rafidi, K ;

Torchia, AJ ;

Stock, JL ;

Hildebrandt, AL ;

Coskran, T ;

Black, SC ;

Brees, DJ ;

Wicks, JR ;

McNeish, JD ;

Coleman, KG .

JOURNAL OF CLINICAL INVESTIGATION, 2003, 112 (02) :197-208

[10] AT7867 Is a Potent and Oral Inhibitor of AKT and p70 S6 Kinase That Induces Pharmacodynamic Changes and Inhibits Human Tumor Xenograft Growth [J].

Grimshaw, Kyla M. ;

Hunter, Lisa-Jane K. ;

Yap, Timothy A. ;

Heaton, Simon P. ;

Walton, Mike I. ;

Woodhead, Steven J. ;

Fazal, Lynsey ;

Reule, Matthias ;

Davies, Thomas G. ;

Seavers, Lisa C. ;

Lock, Victoria ;

Lyons, John F. ;

Thompson, Neil T. ;

Workman, Paul ;

Garrett, Michelle D. .

MOLECULAR CANCER THERAPEUTICS, 2010, 9 (05) :1100-1110

← 1 2 3 4 →